The new administration also affecting the country’s regulatory authority (USFDA in this case) to address issues such as high pricing, clearance of orphan drug request backlog and others affects the healthcare companies that are present in the US as well as the ones that have invested in the country. Healthcare companies that are unaware of these constantly changing regulatory policies may endure a significant loss and lose their interest for investing into markets with high growth potentials.